OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+4.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (1.2M) | 1.4M | — | — | — |
| Cost of Revenue | 1.1M | 756.3K | — | — | 204.7K |
| Gross Profit | (2.3M) | 657.2K | — | — | (204.7K) |
| Operating Expenses | |||||
| R&D Expense | 17.4M | 27.8M | 41.8M | 26.5M | 42.3M |
| SG&A Expense | 36.0M | 39.9M | 29.9M | 26.7M | 20.7M |
| General & Admin Expense | 36.0M | 39.9M | 29.9M | 26.7M | 20.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | (205.0K) |
| Total Operating Expenses | 53.4M | 67.7M | 71.7M | 53.1M | 62.9M |
| Cost and Expenses | 54.5M | 68.5M | 71.7M | 53.1M | 63.1M |
| Operating Income (EBIT) | (55.6M) | (67.1M) | (71.7M) | (53.1M) | (63.1M) |
| Non-Operating | |||||
| Interest Income | 3.00 | 89.7K | 906.1K | 971.5K | — |
| Interest Expense | 264.2K | 283.1K | 3.2M | 2.5M | 1.5M |
| Net Interest Income | (264.2K) | (193.4K) | (2.3M) | (1.6M) | (1.5M) |
| Other Non-Op Income/Expense | (7.0M) | 3.1M | (3.7M) | (5.9M) | (3.0M) |
| Non-Operating Income (excl Interest) | 6.7M | (3.4M) | 503.7K | 3.3M | 1.5M |
| EBT (Pre-Tax Income) | (62.6M) | (64.0M) | (75.4M) | (59.0M) | (66.0M) |
| Income Tax Expense | (1.5M) | (1.6M) | 2.8K | 2.8K | 2.8K |
| Bottom Line | |||||
| Net Income | (61.1M) | (62.4M) | (75.4M) | (59.0M) | (66.1M) |
| Earnings from Cont. Ops | (61.1M) | (62.4M) | (75.4M) | (59.0M) | (66.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (61.1M) | (62.4M) | (75.4M) | (59.0M) | (66.1M) |
| Per Share | |||||
| Basic EPS | ($1.87) | ($1.79) | ($4.06) | ($4.80) | ($6.23) |
| Diluted EPS | ($1.87) | ($1.79) | ($4.06) | ($4.80) | ($6.23) |
| Revenue Per Share | ($0.05) | $0.06 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 25.5M | 25.5M | 18.5M | 12.5M | 10.6M |
| Diluted Shares Outstanding | 25.5M | 25.5M | 18.5M | 12.5M | 10.6M |
| Profitability Metrics | |||||
| EBITDA | (62.3M) | (63.6M) | (72.1M) | (56.4M) | (64.4M) |
| D&A | 29.7K | 117.1K | 113.9K | 44.2K | 204.7K |
| EBIT | (62.4M) | (63.7M) | (72.2M) | (56.4M) | (64.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026